Burning Rock Biotech Limited (NASDAQ:BNR - Get Free Report) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 72,300 shares, a decrease of 10.3% from the November 15th total of 80,600 shares. Currently, 0.9% of the company's shares are short sold. Based on an average trading volume of 33,600 shares, the short-interest ratio is presently 2.2 days.
Institutional Trading of Burning Rock Biotech
An institutional investor recently bought a new position in Burning Rock Biotech stock. SkyView Investment Advisors LLC acquired a new stake in Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company's stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned approximately 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 30.03% of the company's stock.
Burning Rock Biotech Price Performance
Shares of NASDAQ:BNR traded down $0.21 during midday trading on Friday, reaching $6.73. 5,862 shares of the company's stock were exchanged, compared to its average volume of 13,929. The stock has a market cap of $68.94 million, a price-to-earnings ratio of -2.24 and a beta of 0.60. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $9.99. The firm's 50 day simple moving average is $4.28 and its two-hundred day simple moving average is $5.35.
About Burning Rock Biotech
(
Get Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
